Hoth Therapeutics Inc
NASDAQ:HOTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hoth Therapeutics Inc
Stock-Based Compensation
Hoth Therapeutics Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
Stock-Based Compensation
$1.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Stock-Based Compensation
$1.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Stock-Based Compensation
$553m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
9%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Stock-Based Compensation
$799m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Stock-Based Compensation
$820m
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Stock-Based Compensation
$626m
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
Hoth Therapeutics Inc
Glance View
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The firm is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. The company is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.
See Also
What is Hoth Therapeutics Inc's Stock-Based Compensation?
Stock-Based Compensation
1.4m
USD
Based on the financial report for Sep 30, 2025, Hoth Therapeutics Inc's Stock-Based Compensation amounts to 1.4m USD.
What is Hoth Therapeutics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
24%
Over the last year, the Stock-Based Compensation growth was 74%. The average annual Stock-Based Compensation growth rates for Hoth Therapeutics Inc have been 24% over the past three years .
